OncRef

Clinical Trial: NCT05800366

A Phase II Study of Glofitamab Plus Polatuzumab-R-CHP for Patients With High-risk Diffuse Large B-cell Lymphoma

Status:

RECRUITING

Phase:

Phase 2

Lead Sponsor:Jennifer Crombie, MD
Information Provided By:Dana-Farber Cancer Institute
Last Update Posted:2026-03-05

Study Overview

Brief Summary

The goal of this research study is to evaluate the combination of study drugs, Glofitamab and Polatuzumab, and a standard chemotherapy regimen, R-CHP, as a treatment for high-risk diffuse large B-cell lymphoma.

The names of the treatment interventions involved in this study are:

  • Glofitamab (T-cell bispecific antibody)
  • Polatuzumab (antibody-drug conjugate)
  • R-CHP (a chemotherapy regimen comprised of Rituximab, Cyclophosphamide, Doxorubicin Hydrochloride, and Prednisone)

Official Title

A Phase II Study of Glofitamab Plus Polatuzumab-R-CHP for Patients With High-risk Diffuse Large B-cell Lymphoma

Conditions

Lymphoma, Lymphoma, Large B-Cell, Diffuse

Intervention / Treatment

  • Drug: Glofitamab
  • Drug: Polatuzumab
  • Drug: Rituximab
  • Drug: Doxorubicin Hydrochloride
  • Drug: Cyclophosphamide
  • Drug: Prednisone

Other Study ID Numbers

  • 22-606

Start Date (Actual)

2023-04-06

Primary Completion Date (Estimated)

2026-09-15

Study Completion Date (Estimated)

2029-09-15

Enrollment (Estimated)

41

Study Type

Interventional

Phase

Phase 2